ZYF Lopsking Material Technology (002333.SZ): Appointing Wang Xiaoming as the General Manager.
Luposkin (002333.SZ) announced that the company's board of directors recently received a written resignation from General Manager Gong Changyi...
ZYF Lopsking Material Technology (002333.SZ) announced that the company's board of directors recently received a written resignation report from the general manager, Gong Changyi. In consideration of the company's operational needs and personal work arrangements, Gong Changyi has applied to resign from the position of general manager, with the resignation report taking effect from the date of delivery to the board of directors. After resignation, Gong Changyi will continue to serve as the chairman of the company and as a member of the board's special committee.
On December 27, 2024, the company held its seventeenth meeting of the sixth board of directors, where the proposal for appointing the general manager was approved. Nominated by the chairman Gong Changyi and approved by the board of directors' nomination committee, the board of directors agreed to appoint Wang Xiaoming as the company's general manager, with a term from the date of approval at this meeting until the end of the sixth board of directors' term.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025